Published in Biotech Business Week, April 2nd, 2007
Sunitinib malate is an oral therapy belonging to a new class of dual-action multi-targeted drugs that...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.